T cell-based immunotherapies in solid tumors

xlomafota13 shared this article with you from Inoreader T cell-based immunotherapies in solid tumors Via Association française pour l'étude du cancer Bull Cancer. 2021 Oct;108(10S):S96-S108. doi: 10.1016/j.bulcan.2021.06.004. ABSTRACT In solid tumors, adoptive T cell therapies based on ex vivo amplification of antitumor T cell are represented by three main complementary approaches : (i) tumor infiltrating lymphocytes (TILs) which are amplified in vitro before reinjection to the patient, (ii) chimeric antigen receptor (CAR) engineered T cells and (iii) T cell receptor (TCR) engineered T cells. Despite encouraging results, some obstacles remain, such as optimal target selection and tumor microenvironment. In this Review, we discuss pros and cons of these different therapeutic strategies that may open new perspectives in the treatment of solid tumors. PMID:34920813 | DOI:10.1016/j.bulcan.2021.06.004 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.